ArticlePreventive medicine reports2026
The association between state cannabis legalization and non-fatal opioid poisonings among adults with employer-sponsored insurance in the United States.
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Although many states have legalized medical and recreational cannabis, its association with non-fatal opioid poisonings remains unclear. This study examines the association between state cannabis legalization policies and non-fatal opioid poisoning diagnoses among enrollees in employer-sponsored health insurance. Methods: The study included 107,480,711 enrollees aged 18-64 with ≥1 year of continuous enrollment (average age 41; 52% females) in the Merative MarketScan Commercial Claims and Encounters Database (2011-2021) in the United States. Utilizing a staggered adoption difference-in-differences regression, this study compared non-fatal opioid poisoning rates in cannabis-legalized and non-legalized states before and after legalization. Four policies were examined: medical cannabis legalization, medical cannabis dispensary opening (MCD), home medical cannabis cultivation, and recreational cannabis legalization (RCL). Results: State MCDs and RCLs were associated with 15.47% (coefficient = -1.73; 95%CI: -2.72, -0.74) and 11.92% (coefficient = -1.33; 95%CI: -2.30, -0.37) reductions in non-fatal opioid poisonings per 100,000 enrollees per quarter, respectively. Reductions associated with MCDs were significant in ages 18-34, males and females, those without prescription opioids or cannabis use disorder diagnoses within the past year, and outpatient service users. Conclusions: State MCDs and RCLs were associated with significant reductions in non-fatal opioid poisonings in the employer-sponsored insured population, particularly among male and younger populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.